Related Experiment Video
Updated: Jul 15, 2026
Training Persons with Spinal Cord Injury to Ambulate Using a Powered Exoskeleton
Published on: June 16, 2016
Practical applicability and effectiveness of passive, back-support exoskeletons in logistics and care: a randomized
Wendi Sieber1, Johannes Voß2,3, Roberto Falz4,5
1Department of Rehabilitation Psychology and Clinical Neuropsychology, Magdeburg-Stendal University of Applied Sciences, Stendal, Germany.
Background:
Musculoskeletal disorders (MSDs) are the leading work-related health issue in Europe. While passive back-support exoskeletons have shown promise in reducing physical strain in laboratory settings, their medium-term effects under real-world working conditions remain largely unexplored. This study will assess the applicability and the medium-term effects of passive back-support exoskeletons on MSDs in the logistics and healthcare sectors.
Methods:
ELSA LogiCare is a multicenter, parallel-designed, randomized controlled trial. Participants will be randomly assigned in a 2:1 ratio to either an intervention group or a control group. The intervention group will be randomly assigned (1:1) to use one of two passive back-support exoskeleton models for 3 months, while the control group works unassisted as usual. We aim to recruit a total sample size of 120 participants, resulting in approximately 80 participants in the intervention group and 40 participants in the control group. Primary outcomes focus on feasibility and use of the exoskeleton, including daily wearing time. Effectiveness-related outcomes include musculoskeletal complaints after 3 months, assessed using the Cornell Musculoskeletal Discomfort Questionnaire. Secondary outcomes include physical and mental workload (NASA-Raw Task Load Index), job satisfaction (Copenhagen Psychosocial Questionnaire), cognitive performance (Wiener Testsystem), fatigue (Fatigue Scale), acceptance of exoskeletons (Technology Commitment), user satisfaction (Quest 2.0), user experience and implementation barriers (short interviews), absences due to illness, blood pressure, physical activity (Fitbit/Garmin) and dropouts. Outcomes will be assessed at baseline, every 4 weeks during, and immediately after the intervention. The study is open-label, with blinding applied to outcome assessors and data analysts only. Primary analyses will follow the intention-to-treat principle and will be conducted using mixed-effects models with repeated measures to estimate feasibility- and effectiveness-related outcomes over time.
Discussion:
When effectively integrated into workplace environments, passive back-support exoskeletons have the potential to significantly alleviate physical strain and enhance efforts to reduce the risks associated with MSDs. Our process evaluation can also help to understand how passive back-support exoskeletons can be successfully integrated into the logistics and care sectors.
Trial Registration:
German Clinical Trials Register (DRKS) under the DRKS-ID: DRKS00036072.
